Despite the incorporation of CEA and CA199, the performance of the classifier was marginally improved, suggesting that the selected gene panel possesses the CEA/CA199 comparable or even higher power in identifying CRC patients. This evidence concerns the gene CEACAM5 and colorectal carcinoma.